https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2005-12-15 14:07:052016-11-28 14:07:31Dacogen™ (Decitabine) Injection Complete Response Accepted for Review by U.S. FDA
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2005-12-12 14:07:402016-11-28 14:08:03Dacogen™ (Decitabine) Injection Data Presented at American Society of Hematology (ASH) Annual Meeting
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2005-12-06 14:08:492016-11-28 14:09:09Astex Announces New Licensing and Drug Discovery Alliance to Develop Novel Cell Cycle Cancer Drugs
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2005-11-15 14:09:182016-11-28 14:09:43MGI PHARMA and SuperGen Provide Regulatory Status Updates for Dacogen™ (decitabine) Injection for MDS
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2005-09-01 14:10:292016-11-28 14:10:49Approvable Letter Received from the FDA for Dacogen™ (Decitabine) Injection for the Treatment of MDS
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2005-07-27 14:10:592016-11-28 14:11:22AstraZeneca and Astex announce new anti-cancer drug discovery alliance
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2005-06-27 14:12:092016-11-28 14:12:42Astex announces IND approval for novel cancer drug AT7519
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2005-05-23 14:12:452016-11-28 14:13:05Astex announces Clinical Trial Authorization for novel cancer drug AT7519 and plans for two further new drug filings in the next nine months
